A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

ASP7317

subretinal injection

DRUG

tacrolimus

oral

DRUG

trimethoprim-sulfamethoxazole

oral

DRUG

Acyclovir

oral

DRUG

Nystatin

oral

Trial Locations (18)

19107

RECRUITING

Mid-Atlantic Retina, Philadelphia

30322

RECRUITING

Emory University Eye Center, Atlanta

33912

WITHDRAWN

Retina Consultants of Southwest Florida & National Ophthalmic Research Institute, Fort Myers

35203

RECRUITING

Retina Specialty Institute, Pensacola

37203

WITHDRAWN

Tennessee Retina, PC, Nashville

38671

RECRUITING

Deep Blue Retina, Southaven

60452

RECRUITING

University Retina and Macula Associates, Oak Forest

75231

RECRUITING

Retina Foundation of the Southwest, Dallas

78503

COMPLETED

Valley Retina Institute, McAllen

85053

WITHDRAWN

Retinal Consultants of Arizona LTD, Retinal Research Institute, Phoenix

90095

RECRUITING

Jules Stein Eye Institute, Los Angeles

92505

RECRUITING

Kaiser Permanente Riverside Medical Center, Riverside

94303

RECRUITING

Stanford University Byers Eye Institute, Palo Alto

98104

WITHDRAWN

University of Washington, Seattle

99204

RECRUITING

Spokane Eye Clinical Research, Spokane

02114

WITHDRAWN

Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office, Boston

RECRUITING

Ophthalmic Consultants of Boston, Boston

08901

WITHDRAWN

NJ Retina, New Brunswick

All Listed Sponsors
lead

Astellas Institute for Regenerative Medicine

INDUSTRY